Phenytoin-induced reduction of voriconazole serum concentration is not compensated by doubling the dosage.
Alffenaar
Jan-Willem C
JW
van der Elst
Kim C M
KC
Uges
Donald R A
DR
Kosterink
Jos G W
JG
Daenen
Simon M G J
SM
D000927:Anticonvulsants / Q000008:administration & dosage / Q000494:pharmacology*; D000935:Antifungal Agents / Q000493:pharmacokinetics*; D019540:Area Under Curve; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010672:Phenytoin / Q000008:administration & dosage / Q000494:pharmacology*; D055732:Pulmonary Aspergillosis / Q000188:drug therapy; D011743:Pyrimidines / Q000493:pharmacokinetics*; D014230:Triazoles / Q000493:pharmacokinetics*; D065819:Voriconazole
D000927:Anticonvulsants; D000935:Antifungal Agents; D011743:Pyrimidines; D014230:Triazoles; D010672:Phenytoin; D065819:Voriconazole